Zhen Su, CEO and Entrepreneur at Marengo Therapeutics, shared a post on LinkedIn:
“We’re excited to share that the Marengo team will be at the American Association for Cancer Research (AACR) Annual Meeting 2026, where we will present updated clinical data from the ongoing Phase 2a STARt-002 trial evaluating invikafusp alfa in combination with TRODELVY (sacituzumab govitecan-hziy) in metastatic breast cancer.
In this heavily pretreated patient population, including patients with no response to prior therapy, we are now reporting confirmed partial and complete responses across both HR+/HER2− and triple-negative breast cancer cohorts.
We look forward to sharing these data and engaging with the oncology community at AACR 2026.
A special thanks to Dr. Erika Hamilton and START002 Study Investigators.”
DESTINY-Breast09: The Trial Changing the Future of HER2-Positive Breast Cancer
